{"id":"NCT02864251","sponsor":"Bristol-Myers Squibb","briefTitle":"A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy","officialTitle":"Open-Label, Randomized Trial of Nivolumab (BMS-936558) Plus Pemetrexed/Platinum or Nivolumab Plus Ipilimumab (BMS-734016) vs Pemetrexed Plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-03-17","primaryCompletion":"2022-01-20","completion":"2022-10-17","firstPosted":"2016-08-11","resultsPosted":"2023-02-06","lastUpdate":"2023-09-28"},"enrollment":367,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-Small-Cell Lung Carcinoma"],"interventions":[{"type":"BIOLOGICAL","name":"Nivolumab","otherNames":["Opdivo","BMS-936558"]},{"type":"BIOLOGICAL","name":"Ipilimumab","otherNames":["Yervoy","BMS-734016"]},{"type":"DRUG","name":"Pemetrexed","otherNames":[]},{"type":"DRUG","name":"Cisplatin","otherNames":[]},{"type":"DRUG","name":"Carboplatin","otherNames":[]}],"arms":[{"label":"Nivolumab+Platinum doublet chemotherapy","type":"EXPERIMENTAL"},{"label":"Nivolumab + Ipilimumab","type":"EXPERIMENTAL"},{"label":"Platinum doublet chemotherapy","type":"ACTIVE_COMPARATOR"}],"summary":"The main purpose of this study is to determine whether nivolumab + chemotherapy is effective as compared to chemotherapy in the treatment of patients with EGFR mutation, NSCLC who failed first line (1L) or second-line (2L) EGFR TKI therapy.","primaryOutcome":{"measure":"Progression Free Survival (PFS) by Blinded Independent Centralized Review (BICR)","timeFrame":"From randomization to the date of first documented tumor progression or death (approximately 58 months)","effectByArm":[{"arm":"Arm A: Nivolumab Plus Platinum-doublet Chemotherapy","deltaMin":5.59,"sd":null},{"arm":"Arm B: Nivolumab Plus Ipilimumab","deltaMin":1.54,"sd":null},{"arm":"Arm C: Platinum Doublet Chemotherapy","deltaMin":5.45,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0528"},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":7},"locations":{"siteCount":109,"countries":["United States","Canada","China","France","Hong Kong","Japan","Singapore","South Korea","Spain","Taiwan"]},"refs":{"pmids":["38252907"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/s/US/English/USenHome","https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm","https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"]},"adverseEventsSummary":{"seriousAny":{"events":77,"n":141},"commonTop":["Nausea","Anaemia","Constipation","Decreased appetite","Neutrophil count decreased"]}}